Download PDF
Semin Respir Crit Care Med 2022; 43(05): 635-645
DOI: 10.1055/s-0042-1743290
Review Article

FeNO in Asthma

Lola Loewenthal
1   Department of Respiratory Medicine, Royal Brompton and Harefield Hospitals, London, United Kingdom
2   National Heart and Lung Institute, Imperial College London, United Kingdom
,
Andrew Menzies-Gow
1   Department of Respiratory Medicine, Royal Brompton and Harefield Hospitals, London, United Kingdom
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Asthma is a common disease affecting 350 million people worldwide, which is characterized by airways inflammation and hyperreactivity. Historically diagnosis and treatment have been mainly based on symptoms, which have the potential to result in misdiagnosis and inappropriate treatment. Nitric oxide (NO) is exhaled in human breath and is a marker of airways inflammation. Levels of NO are increased in the exhaled breath of patients with type 2 asthma and fractional exhaled nitric oxide (FeNO) provides an objective biomarker of airway inflammation. FeNO testing is an accessible, noninvasive, and easy-to-use test. Cut-off values have been established by the American Thoracic Society (ATS), the Global Initiative for Asthma (GINA), and the National Institute for Health and Care Excellence (NICE) but vary between guidance. FeNO levels have been shown to be predictive of blood and sputum eosinophil levels but should not be used in isolation and current guidance emphasizes the importance of incorporating clinical symptoms and testing when utilizing FeNO results. The inclusion of FeNO testing can increase diagnostic accuracy of asthma, while high levels in asthmatic patients can help predict response to inhaled corticosteroids (ICS) and suppression of levels with ICS to monitor adherence. FeNO levels are also a predictor of asthma risk with increased exacerbation rates and accelerated decline in lung function associated with high levels as well as having an emerging role in predicting response to some biologic therapies in severe asthma. FeNO testing is cost-effective and has been shown, when combined with clinical assessment, to improve asthma management.

Keywords

asthma - biomarkers - diagnosis - fraction of exhaled nitric oxide - management - monitoring - type 2 inflammation


Publication History

Article published online:
04 March 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Global strategy for asthma management and prevention (2021 update). Global Initiative for Asthma, 2021. Accessed January 30, 2022 at: https://ginasthma.org/reports/
    PubMedGoogle Scholar
  • 2 GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 2017; 5 (09) 691-706
    CrossrefPubMedGoogle Scholar
  • 3 National Health Interview Survey data. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention, 2020. Accessed October 7, 2022 at: https://www.cdc.gov/asthma/nhis/2019/data.htm
    PubMedGoogle Scholar
  • 4 Kavanagh J, Jackson DJ, Kent BD. Over- and under-diagnosis in asthma. Breathe (Sheff) 2019; 15 (01) e20-e27
    CrossrefPubMedGoogle Scholar
  • 5 Aaron SD, Vandemheen KL, FitzGerald JM. et al; Canadian Respiratory Research Network. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA 2017; 317 (03) 269-279
    CrossrefPubMedGoogle Scholar
  • 6 Aaron SD, Vandemheen KL, Boulet LP. et al; Canadian Respiratory Clinical Research Consortium. Overdiagnosis of asthma in obese and nonobese adults. CMAJ 2008; 179 (11) 1121-1131
    CrossrefPubMedGoogle Scholar
  • 7 Shaw D, Green R, Berry M. et al. A cross-sectional study of patterns of airway dysfunction, symptoms and morbidity in primary care asthma. Prim Care Respir J 2012; 21 (03) 283-287
    CrossrefPubMedGoogle Scholar
  • 8 Pakhale S, Sumner A, Coyle D, Vandemheen K, Aaron S. (Correcting) misdiagnoses of asthma: a cost effectiveness analysis. BMC Pulm Med 2011; 11: 27
    CrossrefPubMedGoogle Scholar
  • 9 Wu AC, Tantisira K, Li L, Schuemann B, Weiss ST, Fuhlbrigge AL. Childhood Asthma Management Program Research Group. Predictors of symptoms are different from predictors of severe exacerbations from asthma in children. Chest 2011; 140 (01) 100-107
    CrossrefPubMedGoogle Scholar
  • 10 Reddel HK, Busse WW, Pedersen S. et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet 2017; 389 (10065): 157-166
    Google Scholar
  • 11 Chung KF. Personalised medicine in asthma: time for action: Number 1 in the Series “Personalised medicine in respiratory diseases” edited by Renaud Louis and Nicolas Roche. Eur Respir Rev 2017; 26 (145) 170064
    CrossrefPubMedGoogle Scholar
  • 12 Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18 (05) 716-725
    CrossrefPubMedGoogle Scholar
  • 13 Carr TF, Zeki AA, Kraft M. Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med 2018; 197 (01) 22-37
    CrossrefPubMedGoogle Scholar
  • 14 Pavord ID, Beasley R, Agusti A. et al. After asthma: redefining airways diseases. Lancet 2018; 391 (10118): 350-400
    Google Scholar
  • 15 Ray A, Raundhal M, Oriss TB, Ray P, Wenzel SE. Current concepts of severe asthma. J Clin Invest 2016; 126 (07) 2394-2403
    CrossrefPubMedGoogle Scholar
  • 16 Fahy JV. Type 2 inflammation in asthma–present in most, absent in many. Nat Rev Immunol 2015; 15 (01) 57-65
    CrossrefPubMedGoogle Scholar
  • 17 Lloyd CM, Snelgrove RJ. Type 2 immunity: expanding our view. Sci Immunol 2018; 3 (25) 3
    CrossrefPubMedGoogle Scholar
  • 18 Woodruff PG, Modrek B, Choy DF. et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180 (05) 388-395
    CrossrefPubMedGoogle Scholar
  • 19 Humbert M, Beasley R, Ayres J. et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60 (03) 309-316
    CrossrefPubMedGoogle Scholar
  • 20 Ortega HG, Liu MC, Pavord ID. et al; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371 (13) 1198-1207
    CrossrefPubMedGoogle Scholar
  • 21 FitzGerald JM, Bleecker ER, Nair P. et al; CALIMA Study Investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388 (10056): 2128-2141
    CrossrefPubMedGoogle Scholar
  • 22 Castro M, Corren J, Pavord ID. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378 (26) 2486-2496
    Google Scholar
  • 23 Castro M, Zangrilli J, Wechsler ME. et al. Reslizumab treatment for moderate to severe asthma with elevated blood eosinophil levels. J Allergy Clin Immunol 2015; 135: Ab381
    CrossrefPubMedGoogle Scholar
  • 24 Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet 2018; 391 (10122): 783-800
    Google Scholar
  • 25 Kulkarni NS, Hollins F, Sutcliffe A. et al. Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma. J Allergy Clin Immunol 2010; 126 (01) 61-9.e3
    CrossrefPubMedGoogle Scholar
  • 26 Wenzel SE. Emergence of biomolecular pathways to define novel asthma phenotypes. Type-2 immunity and beyond. Am J Respir Cell Mol Biol 2016; 55 (01) 1-4
    CrossrefPubMedGoogle Scholar
  • 27 Kim H, Ellis AK, Fischer D. et al. Asthma biomarkers in the age of biologics. Allergy Asthma Clin Immunol 2017; 13: 48
    CrossrefPubMedGoogle Scholar
  • 28 Russell RJ, Brightling C. Pathogenesis of asthma: implications for precision medicine. Clin Sci (Lond) 2017; 131 (14) 1723-1735
    CrossrefPubMedGoogle Scholar
  • 29 Dweik RA, Boggs PB, Erzurum SC. et al; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184 (05) 602-615
    Google Scholar
  • 30 Lane C, Knight D, Burgess S. et al. Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breath. Thorax 2004; 59 (09) 757-760
    CrossrefPubMedGoogle Scholar
  • 31 Lipworth B, Kuo CR, Chan R. 2020 updated asthma guidelines: clinical utility of fractional exhaled nitric oxide (FENO) in asthma management. J Allergy Clin Immunol 2020; 146 (06) 1281-1282
    CrossrefPubMedGoogle Scholar
  • 32 Ozkan M, Dweik RA, Laskowski D, Arroliga AC, Erzurum SC. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung 2001; 179 (04) 233-243
    CrossrefPubMedGoogle Scholar
  • 33 National Institute for Health and Care Excellence (NICE). Asthma: Diagnosis, Monitoring and Chronic Asthma Management. London: NICE; 2017
    PubMedGoogle Scholar
  • 34 Menzies-Gow A, Corren J, Bourdin A. et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med 2021; 384 (19) 1800-1809
    Google Scholar
  • 35 Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987; 84 (24) 9265-9269
    CrossrefPubMedGoogle Scholar
  • 36 Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333 (6174): 664-666
    CrossrefPubMedGoogle Scholar
  • 37 Antosova M, Mokra D, Pepucha L. et al. Physiology of nitric oxide in the respiratory system. Physiol Res 2017; 66 (Suppl. 02) S159-S172
    CrossrefPubMedGoogle Scholar
  • 38 Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352 (21) 2163-2173
    CrossrefPubMedGoogle Scholar
  • 39 Barnes PJ, Kharitonov SA. Exhaled nitric oxide: a new lung function test. Thorax 1996; 51 (03) 233-237
    CrossrefPubMedGoogle Scholar
  • 40 Moncada S, Palmer RM, Higgs EA. Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol 1989; 38 (11) 1709-1715
    CrossrefPubMedGoogle Scholar
  • 41 Hoyte FCL, Gross LM, Katial RK. Exhaled nitric oxide: an update. Immunol Allergy Clin North Am 2018; 38 (04) 573-585
    CrossrefPubMedGoogle Scholar
  • 42 Guo FH, De Raeve HR, Rice TW, Stuehr DJ, Thunnissen FB, Erzurum SC. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc Natl Acad Sci U S A 1995; 92 (17) 7809-7813
    CrossrefPubMedGoogle Scholar
  • 43 Di Rosa M, Radomski M, Carnuccio R, Moncada S. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun 1990; 172 (03) 1246-1252
    CrossrefPubMedGoogle Scholar
  • 44 Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A 1990; 87 (24) 10043-10047
    CrossrefPubMedGoogle Scholar
  • 45 Ricciardolo FLM. Multiple roles of nitric oxide in the airways. Thorax 2003; 58 (02) 175-182
    CrossrefPubMedGoogle Scholar
  • 46 Saleh D, Ernst P, Lim S, Barnes PJ, Giaid A. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. FASEB J 1998; 12 (11) 929-937
    CrossrefPubMedGoogle Scholar
  • 47 Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric oxide in health and disease of the respiratory system. Physiol Rev 2004; 84 (03) 731-765
    CrossrefPubMedGoogle Scholar
  • 48 Kacmarek RM, Ripple R, Cockrill BA, Bloch KJ, Zapol WM, Johnson DC. Inhaled nitric oxide. A bronchodilator in mild asthmatics with methacholine-induced bronchospasm. Am J Respir Crit Care Med 1996; 153 (01) 128-135
    CrossrefPubMedGoogle Scholar
  • 49 Belvisi MG, Stretton CD, Yacoub M, Barnes PJ. Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. Eur J Pharmacol 1992; 210 (02) 221-222
    CrossrefPubMedGoogle Scholar
  • 50 Holguin F, Grasemann H, Sharma S. et al. L-Citrulline increases nitric oxide and improves control in obese asthmatics. JCI Insight 2019; 4 (24) 4
    CrossrefPubMedGoogle Scholar
  • 51 Barnes PJ. NO or no NO in asthma?. Thorax 1996; 51 (02) 218-220
    CrossrefPubMedGoogle Scholar
  • 52 Schiller B, Hammer J, Barben J, Trachsel D. Comparability of a hand-held nitric oxide analyser with online and offline chemiluminescence-based nitric oxide measurement. Pediatr Allergy Immunol 2009; 20 (07) 679-685
    CrossrefPubMedGoogle Scholar
  • 53 Heaney LG, Busby J, Bradding P. et al; Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK). Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma. Am J Respir Crit Care Med 2019; 199 (04) 454-464
    CrossrefPubMedGoogle Scholar
  • 54 Menzies-Gow A, Mansur AH, Brightling CE. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J 2020; 55 (03) 1901633
    CrossrefPubMedGoogle Scholar
  • 55 American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171 (08) 912-930
    CrossrefPubMedGoogle Scholar
  • 56 Kuo CR, Spears M, Haughney J. et al. Scottish consensus statement on the role of FeNO in adult asthma. Respir Med 2019; 155: 54-57
    CrossrefPubMedGoogle Scholar
  • 57 Holguin F, Cardet JC, Chung KF. et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2020; 55 (01) 55
    CrossrefPubMedGoogle Scholar
  • 58 Price DB, Buhl R, Chan A. et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med 2018; 6 (01) 29-39
    CrossrefPubMedGoogle Scholar
  • 59 Amur S, LaVange L, Zineh I, Buckman-Garner S, Woodcock J. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin Pharmacol Ther 2015; 98 (01) 34-46
    CrossrefPubMedGoogle Scholar
  • 60 Tiotiu A. Biomarkers in asthma: state of the art. Asthma Res Pract 2018; 4: 10
    CrossrefPubMedGoogle Scholar
  • 61 Robinson D, Humbert M, Buhl R. et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy 2017; 47 (02) 161-175
    CrossrefPubMedGoogle Scholar
  • 62 Pizzichini E, Pizzichini MM, Efthimiadis A. et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996; 154 (2, Pt 1): 308-317
    CrossrefPubMedGoogle Scholar
  • 63 Djukanović R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J Suppl 2002; 37: 1s-2s
    CrossrefPubMedGoogle Scholar
  • 64 Tenero L, Zaffanello M, Piazza M, Piacentini G. Measuring airway inflammation in asthmatic children. Front Pediatr 2018; 6: 196
    CrossrefPubMedGoogle Scholar
  • 65 Westerhof GA, Korevaar DA, Amelink M. et al. Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. Eur Respir J 2015; 46 (03) 688-696
    CrossrefPubMedGoogle Scholar
  • 66 Lugogo N, Green CL, Agada N. et al. Obesity's effect on asthma extends to diagnostic criteria. J Allergy Clin Immunol 2018; 141 (03) 1096-1104
    CrossrefPubMedGoogle Scholar
  • 67 Holguin F, Comhair SA, Hazen SL. et al. An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype. Am J Respir Crit Care Med 2013; 187 (02) 153-159
    CrossrefPubMedGoogle Scholar
  • 68 Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 2001; 164 (8, Pt 1): 1376-1381
    CrossrefPubMedGoogle Scholar
  • 69 McNicholl DM, Stevenson M, McGarvey LP, Heaney LG. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med 2012; 186 (11) 1102-1108
    CrossrefPubMedGoogle Scholar
  • 70 Kreindler JL, Watkins ML, Lettis S, Tal-Singer R, Locantore N. Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD. BMJ Open Respir Res 2016; 3 (01) e000151
    CrossrefPubMedGoogle Scholar
  • 71 Oishi K, Hirano T, Suetake R. et al. A trial of oral corticosteroids for persistent systemic and airway inflammation in severe asthma. Immun Inflamm Dis 2017; 5 (03) 261-264
    CrossrefPubMedGoogle Scholar
  • 72 Horváth I, Barnes PJ, Loukides S. et al. A European Respiratory Society technical standard: exhaled biomarkers in lung disease. Eur Respir J 2017; 49 (04) 49
    CrossrefPubMedGoogle Scholar
  • 73 Buchvald F, Baraldi E, Carraro S. et al. Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years. J Allergy Clin Immunol 2005; 115 (06) 1130-1136
    CrossrefPubMedGoogle Scholar
  • 74 Dressel H, de la Motte D, Reichert J. et al. Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height. Respir Med 2008; 102 (07) 962-969
    CrossrefPubMedGoogle Scholar
  • 75 Byrnes CA, Dinarevic S, Busst CA, Shinebourne EA, Bush A. Effect of measurement conditions on measured levels of peak exhaled nitric oxide. Thorax 1997; 52 (08) 697-701
    CrossrefPubMedGoogle Scholar
  • 76 Anderson WJ, Short PM, Williamson PA, Lipworth BJ. Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial. Chest 2012; 142 (06) 1553-1561
    CrossrefPubMedGoogle Scholar
  • 77 Haccuria A, Michils A, Michiels S, Van Muylem A. Exhaled nitric oxide: a biomarker integrating both lung function and airway inflammation changes. J Allergy Clin Immunol 2014; 134 (03) 554-559
    CrossrefPubMedGoogle Scholar
  • 78 Karrasch S, Linde K, Rücker G. et al. Accuracy of FENO for diagnosing asthma: a systematic review. Thorax 2017; 72 (02) 109-116
    Google Scholar
  • 79 Busse WW, Wenzel SE, Casale TB. et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med 2021; 9 (10) 1165-1173
    CrossrefPubMedGoogle Scholar
  • 80 Mansur AH, Srivastava S, Sahal A. Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function. Respir Med 2018; 143: 31-38
    CrossrefPubMedGoogle Scholar
  • 81 Lehtimäki L, Csonka P, Mäkinen E, Isojärvi J, Hovi S-L, Ahovuo-Saloranta A. Predictive value of exhaled nitric oxide in the management of asthma: a systematic review. Eur Respir J 2016; 48 (03) 706-714
    CrossrefPubMedGoogle Scholar
  • 82 Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 2013; 132 (04) 821-7.e1, 5
    CrossrefPubMedGoogle Scholar
  • 83 Buhl R, Korn S, Menzies-Gow A. et al. Prospective, single-arm, longitudinal study of biomarkers in real-world patients with severe asthma. J Allergy Clin Immunol Pract 2020; 8: 2630-2639.e6
    CrossrefPubMedGoogle Scholar
  • 84 Mogensen I, Alving K, Jacinto T, Fonseca J, Janson C, Malinovschi A. Simultaneously elevated FeNO and blood eosinophils relate to asthma morbidity in asthmatics from NHANES 2007-12. Clin Exp Allergy 2018; 48 (08) 935-943
    CrossrefPubMedGoogle Scholar
  • 85 Shim E, Lee E, Yang S-I. et al. The association of lung function, bronchial hyperresponsiveness, and exhaled nitric oxide differs between atopic and non-atopic asthma in children. Allergy Asthma Immunol Res 2015; 7 (04) 339-345
    CrossrefPubMedGoogle Scholar
  • 86 Soto-Ramos M, Castro-Rodríguez JA, Hinojos-Gallardo LC, Hernández-Saldaña R, Cisneros-Castolo M, Carrillo-Rodríguez V. Fractional exhaled nitric oxide has a good correlation with asthma control and lung function in Latino children with asthma. J Asthma 2013; 50 (06) 590-594
    CrossrefPubMedGoogle Scholar
  • 87 Coumou H, Westerhof GA, de Nijs SB, Zwinderman AH, Bel EH. Predictors of accelerated decline in lung function in adult-onset asthma. Eur Respir J 2018; 51 (02) 51
    CrossrefPubMedGoogle Scholar
  • 88 Matsunaga K, Hirano T, Oka A, Ito K, Edakuni N. Persistently high exhaled nitric oxide and loss of lung function in controlled asthma. Allergol Int 2016; 65 (03) 266-271
    CrossrefPubMedGoogle Scholar
  • 89 Nerpin E, Ferreira DS, Weyler J. et al. Bronchodilator response and lung function decline: associations with exhaled nitric oxide with regard to sex and smoking status. World Allergy Organ J 2021; 14 (05) 100544
    CrossrefPubMedGoogle Scholar
  • 90 Petsky HL, Cates CJ, Kew KM, Chang AB. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax 2018; 73 (12) 1110-1119
    CrossrefPubMedGoogle Scholar
  • 91 Heaney LG, Busby J, Hanratty CE. et al; Investigators for the MRC Refractory Asthma Stratification Programme. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respir Med 2021; 9 (01) 57-68
    CrossrefPubMedGoogle Scholar
  • 92 Hekking P-PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015; 135: 896-902
    Google Scholar
  • 93 Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: is there a solution to the problem?. Ann Allergy Asthma Immunol 1997; 79 (03) 177-185 , quiz 185–186
    CrossrefPubMedGoogle Scholar
  • 94 d'Ancona G, Kavanagh J, Roxas C. et al. Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma. Eur Respir J 2020; 55 (05) 55
    CrossrefPubMedGoogle Scholar
  • 95 Williams LK, Peterson EL, Wells K. et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011; 128 (06) 1185-1191.e2
    CrossrefPubMedGoogle Scholar
  • 96 Couillard S, Shrimanker R, Chaudhuri R. et al. Fractional exhaled nitric oxide nonsuppression identifies corticosteroid-resistant type 2 signaling in severe asthma. Am J Respir Crit Care Med 2021; 204 (06) 731-734
    CrossrefPubMedGoogle Scholar
  • 97 Sullivan PW, Slejko JF, Ghushchyan VH. et al. The relationship between asthma, asthma control and economic outcomes in the United States. J Asthma 2014; 51 (07) 769-778
    CrossrefPubMedGoogle Scholar
  • 98 Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE. TENOR Study Group. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy 2007; 62 (02) 126-133
    CrossrefPubMedGoogle Scholar
  • 99 Busse WW. Biological treatments for severe asthma: a major advance in asthma care. Allergol Int 2019; 68 (02) 158-166
    CrossrefPubMedGoogle Scholar
  • 100 National Institute for Health and Care Excellence (NICE). Omalizumab for treating severe persistent allergic asthma. National Institute for Health and Care Excellence; 2013
    Google Scholar
  • 101 Hanania NA, Wenzel S, Rosén K. et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187 (08) 804-811
    Google Scholar
  • 102 Casale TB, Luskin AT, Busse W. et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract 2019; 7 (01) 156-164.e1
    CrossrefPubMedGoogle Scholar
  • 103 Pavord ID, Korn S, Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380 (9842): 651-659
    CrossrefPubMedGoogle Scholar
  • 104 Haldar P, Brightling CE, Hargadon B. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360 (10) 973-984
    CrossrefPubMedGoogle Scholar
  • 105 Yancey SW, Keene ON, Albers FC. et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol 2017; 140 (06) 1509-1518
    CrossrefPubMedGoogle Scholar
  • 106 Shrimanker R, Keene O, Hynes G, Wenzel S, Yancey S, Pavord ID. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis. Am J Respir Crit Care Med 2019; 200 (10) 1308-1312
    CrossrefPubMedGoogle Scholar
  • 107 Hearn AP, Kavanagh J, d'Ancona G. et al. The relationship between FENO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. J Allergy Clin Immunol Pract 2021; 9: 2093-2096.e1
    CrossrefPubMedGoogle Scholar
  • 108 Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity 2019; 50 (04) 975-991
    CrossrefPubMedGoogle Scholar
  • 109 Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G. Dupilumab: a novel treatment for asthma. J Asthma Allergy 2014; 7: 123-130
    CrossrefPubMedGoogle Scholar
  • 110 Wenzel S, Castro M, Corren J. et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016; 388 (10039): 31-44
    CrossrefPubMedGoogle Scholar
  • 111 Rabe KF, Nair P, Brusselle G. et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018; 378 (26) 2475-2485
    Google Scholar
  • 112 Corren J, Parnes JR, Wang L. et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med 2017; 377 (10) 936-946
    CrossrefPubMedGoogle Scholar
  • 113 Puig-Junoy J, Pascual-Argenté N. Socioeconomic costs of asthma in the European Union, United States and Canada: a systematic review. [in Spanish]. Rev Esp Salud Pública 2017; 91: 91
    PubMedGoogle Scholar
  • 114 National Institute for Health and Care Excellence (NICE). Diagnostics Guidance. Measuring Fractional Exhaled Nitric Oxide Concentration in Asthma: NIOX MINO, NIOX VERO and NObreath: National Institute for Health and Care Excellence (NICE); 2014
    Google Scholar
  • 115 LaForce C, Brooks E, Herje N, Dorinsky P, Rickard K. Impact of exhaled nitric oxide measurements on treatment decisions in an asthma specialty clinic. Ann Allergy Asthma Immunol 2014; 113 (06) 619-623
    CrossrefPubMedGoogle Scholar
  • 116 Arnold RJ, Layton A, Massanari M. Cost impact of monitoring exhaled nitric oxide in asthma management. Allergy Asthma Proc 2018; 39 (05) 338-344
    CrossrefPubMedGoogle Scholar
  • 117 Arnold RJ, Massanari M, Lee TA, Brooks E. A review of the utility and cost effectiveness of monitoring fractional exhaled nitric oxide (FeNO) in asthma management. Manag Care 2018; 27 (07) 34-41
    PubMedGoogle Scholar
  • 118 Honkoop PJ, Loijmans RJ, Termeer EH. et al; Asthma Control Cost-Utility Randomized Trial Evaluation (ACCURATE) Study Group. Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: a cluster-randomized trial in primary care. J Allergy Clin Immunol 2015; 135 (03) 682-8.e11
    CrossrefPubMedGoogle Scholar
  • 119 Brooks EA, Massanari M. Cost-effectiveness analysis of monitoring fractional exhaled nitric oxide (FeNO) in the management of asthma. Manag Care 2018; 27 (07) 42-48
    PubMedGoogle Scholar
  • 120 Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. Allergy 2009; 64 (03) 431-438
    CrossrefPubMedGoogle Scholar
  • 121 Alving K. FeNO and suspected asthma: better to identify responsiveness to treatment than to label with a diagnosis. Lancet Respir Med 2018; 6 (01) 3-5
    CrossrefPubMedGoogle Scholar
  • 122 Developing Lung Function Initiative (GLI) reference equations for exhaled and nasal nitric oxide (TF-2018–07). Accessed October 31, 2021 at: https://www.ersnet.org/research/task-forces
    PubMedGoogle Scholar
  • 123 Quanjer PH, Hall GL, Stanojevic S, Cole TJ, Stocks J. Global Lungs Initiative. Age- and height-based prediction bias in spirometry reference equations. Eur Respir J 2012; 40 (01) 190-197
    CrossrefPubMedGoogle Scholar
  • 124 Heaney LG, Djukanovic R, Woodcock A. et al. Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax 2016; 71 (02) 187-189
    CrossrefPubMedGoogle Scholar
  • 125 Longstaff J, Chauhan M, De Vos R. et al. FeNO Testing for Asthma Diagnosis in Primary Care. European Respiratory Society; 2020
    CrossrefGoogle Scholar
  • 126 Gratziou C, Lignos M, Dassiou M, Roussos C. Influence of atopy on exhaled nitric oxide in patients with stable asthma and rhinitis. Eur Respir J 1999; 14 (04) 897-901
    CrossrefPubMedGoogle Scholar
  • 127 Galli J, Montuschi P, Passàli GC, Laruffa M, Parrilla C, Paludetti G. Exhaled nitric oxide measurement in patients affected by nasal polyposis. Otolaryngol Head Neck Surg 2012; 147 (02) 351-356
    CrossrefPubMedGoogle Scholar